Senseonics (SENS) Investor update summary

Strategic and commercial updates

• Transitioned commercial operations from PHC/Ascensia, integrating their team for seamless execution and greater control over commercial strategy.

• Focused on increasing product awareness, especially through direct-to-consumer (DTC) marketing, resulting in significant new patient growth and improved retention.

• Expanded the ION nurse network to around 80, improving patient access and clinic penetration.

• Achieved over 100% growth in DTC patients and 40% growth in HCPs in Q1, with prescribers up 80% year-on-year.

• 90% of new patients are switching from other CGMs, with a $13B+ market opportunity and strong focus on retention and patient satisfaction.

Product performance and clinical data

• Eversense 365 demonstrated high transmitter wear time (93%), stable glucose metrics over a year, and minimal hypoglycemia.

• Real-world data from over 12,000 sensors shows improved outcomes with age, with Medicare-age patients achieving >70% time in range and >85% meeting hypoglycemic targets.

• Integration with the twiist pump led to best-in-class performance, with median transmitter wear time at 99% and time in range at 76.6%.

• Case studies highlighted significant improvements in glycemic control and patient satisfaction after switching to Eversense and twiist.

Product pipeline and innovation

• Gemini product adds a battery for intermittent scanning, enabling both flash and full-service CGM modes; pivotal study ongoing, aiming for Q2 2027 launch.

• Freedom product will eliminate the on-body transmitter, using Bluetooth for direct communication; first-in-human studies planned for early Q3, targeting Q2 2028 launch.

• Both products maintain the same sensor platform, leveraging proven performance and FDA comfort with the technology.